Narwhal Capital Management boosted its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 32.2% during the second quarter, Holdings Channel reports. The firm owned 72,510 shares of the company’s stock after buying an additional 17,660 shares during the period. Teva Pharmaceutical Industries comprises about 1.1% of Narwhal Capital Management’s holdings, making the stock its 25th largest position. Narwhal Capital Management’s holdings in Teva Pharmaceutical Industries were worth $3,642,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the stock. Flow Traders U.S. LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $105,000. Kistler Tiffany Companies LLC raised its stake in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after buying an additional 64 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of Teva Pharmaceutical Industries by 1,127.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,210 shares of the company’s stock valued at $118,000 after buying an additional 2,030 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $1,194,000. Finally, Cribstone Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $161,000.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 0.24% during trading on Wednesday, reaching $50.48. 3,351,448 shares of the company’s stock traded hands. The company has a 50 day moving average price of $52.20 and a 200 day moving average price of $53.27. The stock has a market capitalization of $46.14 billion, a PE ratio of 33.72 and a beta of 0.82. Teva Pharmaceutical Industries Ltd has a 1-year low of $48.01 and a 1-year high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.05. The business earned $5 billion during the quarter, compared to analyst estimates of $4.86 billion. During the same period in the previous year, the business posted $1.43 earnings per share. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd will post $5.26 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Monday, August 22nd were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend was Thursday, August 18th.

Several equities research analysts recently commented on the stock. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, June 15th. Mizuho reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Sunday, July 17th. RBC Capital Markets set a $71.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Sunday, September 11th. Piper Jaffray Cos. reissued a “neutral” rating and issued a $57.00 price target (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. cut their price target on shares of Teva Pharmaceutical Industries from $77.00 to $72.00 and set an “outperform” rating for the company in a report on Thursday, July 14th. Seven investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average price target of $67.54.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.